Scadden David 4
4 · AGIOS PHARMACEUTICALS, INC. · Filed Nov 14, 2025
Insider Transaction Report
Form 4
Scadden David
Director
Transactions
- Sale
Common stock
2025-11-12$43.84/sh−200$8,768→ 17,603 total - Exercise/Conversion
Stock options (right to buy)
2025-11-12−200→ 26,907 totalExercise: $18.09Exp: 2032-06-21→ Common stock (200 underlying) - Exercise/Conversion
Common stock
2025-11-12$18.09/sh+200$3,618→ 17,803 total
Footnotes (2)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]This option was granted on June 21, 2022. The shares underlying this option vest 100% one year from grant date.